Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: Implications for dose optimization

Pedram Heidari, Eric Wehrenberg-Klee, Peiman Habibollahi, Daniel Yokell, Matthew Kulke, Umar Mahmood

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Somatostatin receptors (SSTR) are highly expressed in well-differentiated neuroendocrine tumors (NET). Octreotide, an SSTR agonist, has been used to suppress the production of vasoactive hormones and relieve symptoms of hormone hypersecretion with functional NETs. In a clinical trial, an empiric dose of octreotide treatment prolonged time to tumor progression in patients with small bowel neuroendocrine (carcinoid) tumors, irrespective of symptom status. However, there has yet to be a dose optimization study across the patient population, and methods are currently lacking to optimize dosing of octreotide therapy on an individual basis. Multiple factors such as total tumor burden, receptor expression levels, and nontarget organ metabolism/excretion may contribute to a variation in SSTR octreotide occupancy with a given dose among different patients. In this study, we report the development of an imaging method to measure surface SSTR expression and occupancy level using the PET radiotracer 68Ga-DOTATOC. In an animal model, SSTR occupancy by octreotide was assessed quantitatively with 68Ga-DOTATOC PET, with the finding that increased occupancy resulted in decreased tumor proliferation rate. The results suggested that quantitative SSTR imaging during octreotide therapy has the potential to determine the fractional receptor occupancy in NETs, thereby allowing octreotide dosing to be optimized readily in individual patients. Clinical trials validating this approach are warranted.

Original languageEnglish (US)
Pages (from-to)6865-6873
Number of pages9
JournalCancer Research
Volume73
Issue number23
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Somatostatin Receptors
Octreotide
Neuroendocrine Tumors
Clinical Trials
Hormones
Carcinoid Tumor
Tumor Burden
Neoplasms
Therapeutics
Animal Models
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model : Implications for dose optimization. / Heidari, Pedram; Wehrenberg-Klee, Eric; Habibollahi, Peiman; Yokell, Daniel; Kulke, Matthew; Mahmood, Umar.

In: Cancer Research, Vol. 73, No. 23, 01.12.2013, p. 6865-6873.

Research output: Contribution to journalArticle

Heidari, Pedram ; Wehrenberg-Klee, Eric ; Habibollahi, Peiman ; Yokell, Daniel ; Kulke, Matthew ; Mahmood, Umar. / Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model : Implications for dose optimization. In: Cancer Research. 2013 ; Vol. 73, No. 23. pp. 6865-6873.
@article{906afe85adae461da09bfd07b658c4b7,
title = "Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: Implications for dose optimization",
abstract = "Somatostatin receptors (SSTR) are highly expressed in well-differentiated neuroendocrine tumors (NET). Octreotide, an SSTR agonist, has been used to suppress the production of vasoactive hormones and relieve symptoms of hormone hypersecretion with functional NETs. In a clinical trial, an empiric dose of octreotide treatment prolonged time to tumor progression in patients with small bowel neuroendocrine (carcinoid) tumors, irrespective of symptom status. However, there has yet to be a dose optimization study across the patient population, and methods are currently lacking to optimize dosing of octreotide therapy on an individual basis. Multiple factors such as total tumor burden, receptor expression levels, and nontarget organ metabolism/excretion may contribute to a variation in SSTR octreotide occupancy with a given dose among different patients. In this study, we report the development of an imaging method to measure surface SSTR expression and occupancy level using the PET radiotracer 68Ga-DOTATOC. In an animal model, SSTR occupancy by octreotide was assessed quantitatively with 68Ga-DOTATOC PET, with the finding that increased occupancy resulted in decreased tumor proliferation rate. The results suggested that quantitative SSTR imaging during octreotide therapy has the potential to determine the fractional receptor occupancy in NETs, thereby allowing octreotide dosing to be optimized readily in individual patients. Clinical trials validating this approach are warranted.",
author = "Pedram Heidari and Eric Wehrenberg-Klee and Peiman Habibollahi and Daniel Yokell and Matthew Kulke and Umar Mahmood",
year = "2013",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-13-1199",
language = "English (US)",
volume = "73",
pages = "6865--6873",
journal = "Cancer Research",
issn = "0008-5472",
number = "23",

}

TY - JOUR

T1 - Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model

T2 - Implications for dose optimization

AU - Heidari, Pedram

AU - Wehrenberg-Klee, Eric

AU - Habibollahi, Peiman

AU - Yokell, Daniel

AU - Kulke, Matthew

AU - Mahmood, Umar

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Somatostatin receptors (SSTR) are highly expressed in well-differentiated neuroendocrine tumors (NET). Octreotide, an SSTR agonist, has been used to suppress the production of vasoactive hormones and relieve symptoms of hormone hypersecretion with functional NETs. In a clinical trial, an empiric dose of octreotide treatment prolonged time to tumor progression in patients with small bowel neuroendocrine (carcinoid) tumors, irrespective of symptom status. However, there has yet to be a dose optimization study across the patient population, and methods are currently lacking to optimize dosing of octreotide therapy on an individual basis. Multiple factors such as total tumor burden, receptor expression levels, and nontarget organ metabolism/excretion may contribute to a variation in SSTR octreotide occupancy with a given dose among different patients. In this study, we report the development of an imaging method to measure surface SSTR expression and occupancy level using the PET radiotracer 68Ga-DOTATOC. In an animal model, SSTR occupancy by octreotide was assessed quantitatively with 68Ga-DOTATOC PET, with the finding that increased occupancy resulted in decreased tumor proliferation rate. The results suggested that quantitative SSTR imaging during octreotide therapy has the potential to determine the fractional receptor occupancy in NETs, thereby allowing octreotide dosing to be optimized readily in individual patients. Clinical trials validating this approach are warranted.

AB - Somatostatin receptors (SSTR) are highly expressed in well-differentiated neuroendocrine tumors (NET). Octreotide, an SSTR agonist, has been used to suppress the production of vasoactive hormones and relieve symptoms of hormone hypersecretion with functional NETs. In a clinical trial, an empiric dose of octreotide treatment prolonged time to tumor progression in patients with small bowel neuroendocrine (carcinoid) tumors, irrespective of symptom status. However, there has yet to be a dose optimization study across the patient population, and methods are currently lacking to optimize dosing of octreotide therapy on an individual basis. Multiple factors such as total tumor burden, receptor expression levels, and nontarget organ metabolism/excretion may contribute to a variation in SSTR octreotide occupancy with a given dose among different patients. In this study, we report the development of an imaging method to measure surface SSTR expression and occupancy level using the PET radiotracer 68Ga-DOTATOC. In an animal model, SSTR occupancy by octreotide was assessed quantitatively with 68Ga-DOTATOC PET, with the finding that increased occupancy resulted in decreased tumor proliferation rate. The results suggested that quantitative SSTR imaging during octreotide therapy has the potential to determine the fractional receptor occupancy in NETs, thereby allowing octreotide dosing to be optimized readily in individual patients. Clinical trials validating this approach are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84890280115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890280115&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-1199

DO - 10.1158/0008-5472.CAN-13-1199

M3 - Article

C2 - 24080280

AN - SCOPUS:84890280115

VL - 73

SP - 6865

EP - 6873

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 23

ER -